{
    "xml": "<topic id=\"PHP1505\" outputclass=\"drug\" rev=\"1.11\" type=\"drug\" namespace=\"/drugs/dabigatran-etexilate\" basename=\"dabigatran-etexilate\" title=\"DABIGATRAN ETEXILATE\">\n<title>DABIGATRAN ETEXILATE</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1120\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/dabigatran\">Dabigatran</xref>\n</p>\n<data name=\"vtmid\">13568411000001103</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_385077519\" title=\"Thrombin inhibitors\">Thrombin inhibitors</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP69700\" outputclass=\"drugAction\" rev=\"1.11\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Drug action</title>\n<body>\n<section>\n<sectiondiv>\n<p>Dabigatran etexilate is a direct thrombin inhibitor with a rapid onset of action.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69607\" outputclass=\"indicationsAndDose\" rev=\"1.65\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism following total knee replacement surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;74 years</p>\n<p>110&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 220&#8239;mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 75 years and over</p>\n<p>75&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 150&#8239;mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism following total knee replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>110&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 150&#8239;mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism following total hip replacement surgery</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;74 years</p>\n<p>110&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 220&#8239;mg once daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 75 years and over</p>\n<p>75&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 150&#8239;mg once daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of venous thromboembolism following total hip replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>110&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 150&#8239;mg daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of deep-vein thrombosis</p>\n<p outputclass=\"therapeuticIndication\">Treatment of pulmonary embolism</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent deep-vein thrombosis</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent pulmonary embolism</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;74 years</p>\n<p>150&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 75&#8211;79 years</p>\n<p>110&#8211;150&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 80 years and over</p>\n<p>110&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of deep-vein thrombosis in patients with moderate renal impairment</p>\n<p outputclass=\"therapeuticIndication\">Treatment of deep-vein thrombosis in patients at increased risk of bleeding</p>\n<p outputclass=\"therapeuticIndication\">Treatment of pulmonary embolism in patients with moderate renal impairment</p>\n<p outputclass=\"therapeuticIndication\">Treatment of pulmonary embolism in patients at increased risk of bleeding</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent deep-vein thrombosis in patients with moderate renal impairment</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent deep-vein thrombosis in patients at increased risk of bleeding</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent pulmonary embolism in patients with moderate renal impairment</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent pulmonary embolism in patients at increased risk of bleeding</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>110&#8211;150&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of deep-vein thrombosis in patients receiving concomitant treatment with verapamil</p>\n<p outputclass=\"therapeuticIndication\">Treatment of pulmonary embolism in patients receiving concomitant treatment with verapamil</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent deep-vein thrombosis in patients receiving concomitant treatment with verapamil</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of recurrent pulmonary embolism in patients receiving concomitant treatment with verapamil</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>110&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult 18&#8211;74 years</p>\n<p>150&#8239;mg twice daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 75&#8211;79 years</p>\n<p>110&#8211;150&#8239;mg twice daily.</p>\n</li>\n<li outputclass=\"patientGroup adult\">\n<p>Adult 80 years and over</p>\n<p>110&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension in patients receiving concomitant treatment with verapamil</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>110&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension, in patients at increased risk of bleeding</p>\n<p outputclass=\"therapeuticIndication\">Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension, in patients with moderate renal impairment</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By mouth</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>110&#8211;150&#8239;mg twice daily.</p>\n</li>\n</ul>\n</section>\n<section outputclass=\"doseEquivalence\">\n<title>Dose equivalence and conversion</title>\n<p>For information on changing from, or to, other anticoagulants, consult product literature.</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69734\" outputclass=\"contraindications\" rev=\"1.10\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"contraindications\">\n<p>\n<ph outputclass=\"contraindication\">Active bleeding</ph>; <ph outputclass=\"contraindication\">do not use as anticoagulant for prosthetic heart valve</ph>; <ph outputclass=\"contraindication\">malignant neoplasms</ph>; <ph outputclass=\"contraindication\">oesophageal varices</ph>; <ph outputclass=\"contraindication\">recent brain surgery</ph>; <ph outputclass=\"contraindication\">recent gastro-intestinal ulcer</ph>; <ph outputclass=\"contraindication\">recent intracranial haemorrhage</ph>; <ph outputclass=\"contraindication\">recent ophthalmic surgery</ph>; <ph outputclass=\"contraindication\">recent spine surgery</ph>; <ph outputclass=\"contraindication\">significant risk of major bleeding</ph>; <ph outputclass=\"contraindication\">vascular aneurysm</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69800\" outputclass=\"cautions\" rev=\"1.13\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"cautions\">\n<p>\n<ph outputclass=\"caution\">Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;give initial dose at least 2 hours after catheter removal and monitor neurological signs)</ph>; <ph outputclass=\"caution\">bacterial endocarditis</ph>; <ph outputclass=\"caution\">bleeding disorders</ph>; <ph outputclass=\"caution\">body-weight less than 50&#8239;kg</ph>; <ph outputclass=\"caution\">elderly</ph>; <ph outputclass=\"caution\">gastritis</ph>; <ph outputclass=\"caution\">gastro-oesophageal reflux</ph>; <ph outputclass=\"caution\">oesophagitis</ph>; <ph outputclass=\"caution\">recent biopsy</ph>; <ph outputclass=\"caution\">recent major trauma</ph>; <ph outputclass=\"caution\">thrombocytopenia</ph>\n</p>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69593\" outputclass=\"interactions\" rev=\"1.11\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (dabigatran).</p>\n<p>Caution in concomitant use of drugs that increase risk of bleeding.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69522\" outputclass=\"sideEffects\" rev=\"1.8\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"generalSideEffects\">\n<sectiondiv outputclass=\"frequencies\">\n<sectiondiv outputclass=\"commonOrVeryCommon\">\n<p outputclass=\"title\">Common or very common</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Abdominal pain</ph>; <ph outputclass=\"sideEffect\">anaemia</ph>; <ph outputclass=\"sideEffect\">diarrhoea</ph>; <ph outputclass=\"sideEffect\">dyspepsia</ph>; <ph outputclass=\"sideEffect\">haemorrhage</ph>; <ph outputclass=\"sideEffect\">nausea</ph>\n</p>\n</sectiondiv>\n<sectiondiv outputclass=\"uncommon\">\n<p outputclass=\"title\">Uncommon</p>\n<p outputclass=\"sideEffects\">\n<ph outputclass=\"sideEffect\">Dysphagia</ph>; <ph outputclass=\"sideEffect\">gastro-intestinal ulcer</ph>; <ph outputclass=\"sideEffect\">gastro-oesophageal reflux</ph>; <ph outputclass=\"sideEffect\">hepatobiliary disorders</ph>; <ph outputclass=\"sideEffect\">oesophagitis</ph>; <ph outputclass=\"sideEffect\">thrombocytopenia</ph>; <ph outputclass=\"sideEffect\">vomiting</ph>\n</p>\n</sectiondiv>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69578\" outputclass=\"pregnancy\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid unless essential&#8212;toxicity in <i>animal </i>studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69828\" outputclass=\"breastFeeding\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Manufacturer advises avoid&#8212;no information available.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69668\" outputclass=\"hepaticImpairment\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Hepatic impairment</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid in severe liver disease, especially if prothrombin time already prolonged.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69545\" outputclass=\"renalImpairment\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Renal impairment</title>\n<body>\n<section outputclass=\"doseAdjustments\">\n<sectiondiv>\n<p>For <i>prophylaxis of venous thromboembolism following knee or hip replacement surgery</i>, reduce initial dose to 75&#8239;mg and subsequent doses to 150&#8239;mg once daily if creatinine clearance 30&#8211;50&#8239;mL/ minute; reduce dose to 75&#8239;mg once daily if creatinine clearance 30&#8211;50&#8239;mL/minute and patient receiving concomitant treatment with verapamil.</p>\n<p>For <i>treatment of deep-vein thrombosis and pulmonary embolism, prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism, prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation,</i> consider reduced dose of 110&#8239;mg twice daily if creatinine clearance 30&#8211;50&#8239;mL/minute, based on individual assessment of thromboembolic risk and risk of bleeding.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid if creatinine clearance less than 30&#8239;mL/minute.</p>\n</sectiondiv>\n</section>\n<section outputclass=\"additionalMonitoringInRenalImpairment\">\n<sectiondiv>\n<p>In renal impairment monitor renal function at least annually (manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69478\" outputclass=\"monitoringRequirements\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.</p>\n<p>No routine anticoagulant monitoring required (INR tests are unreliable).</p>\n<p>Assess renal function (manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance) before treatment in all patients and at least annually in elderly.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69862\" outputclass=\"directionsForAdministration\" rev=\"1.15\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Directions for administration</title>\n<body>\n<section>\n<sectiondiv>\n<p>When given concomitantly with amiodarone or verapamil, doses should be taken at the same time.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP57168\" outputclass=\"prescribingAndDispensingInformation\" rev=\"1.32\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Prescribing and dispensing information</title>\n<body>\n<section>\n<sectiondiv>\n<p>Dabigatran etexilate, is given orally for prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery; it is also licensed for the treatment of deep-vein thrombosis and pulmonary embolism, and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism in adults. Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilisation, and longer duration of treatment should be based on permanent risk factors, or idiopathic deep-vein thrombosis or pulmonary embolism.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP69440\" outputclass=\"nationalFunding\" rev=\"1.24\" parent=\"/drugs/dabigatran-etexilate\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA157</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (September 2008)</p>\r\n<p>Dabigatran etexilate is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA157\">www.nice.org.uk/TA157</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA249</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (March 2012)</p>\r\n<p>Dabigatran etexilate is an option for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with one or more of the following risk factors:</p>\r\n<ul>\r\n<li>previous stroke, transient ischaemic attack, or systemic embolism</li>\r\n<li>left ventricular ejection fraction &lt;40%</li>\r\n<li>symptomatic heart failure</li>\r\n<li>age &#8805;75 years</li>\r\n<li>age &#8805;65 years in patients with diabetes mellitus, coronary artery disease, or hypertension</li>\r\n</ul>\r\n<p>The risks and benefits of dabigatran compared to warfarin should be discussed with the patient.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA249\">www.nice.org.uk/TA249</xref>\n</sectiondiv>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA327</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and /or pulmonary embolism (December 2014)</p>\r\n<p>Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA327\">www.nice.org.uk/TA327</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP1505-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/dabigatran-etexilate\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77319\" title=\"Capsule\" namespace=\"/drugs/dabigatran-etexilate/capsule\">Capsule</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP98619\" namespace=\"/guidance/prescribing-in-dental-practice\" title=\"Prescribing in dental practice\" count=\"1\" rel=\"backlink\">Prescribing in dental practice</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#bnf_d1e27097\" href=\"#bnf_d1e27097\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/dabigatran\" title=\"\" count=\"1\" rel=\"backlink\">bnf_d1e27097</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#bnf_d1e27418\" href=\"#bnf_d1e27418\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/dabigatran\" title=\"\" count=\"1\" rel=\"backlink\">bnf_d1e27418</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#bnf_d1e11888\" href=\"#bnf_d1e11888\" namespace=\"/interactions/list-of-drug-interactions/anti-arrhythmics/amiodarone\" title=\"\" count=\"1\" rel=\"backlink\">bnf_d1e11888</xref>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_118\" namespace=\"/interactions/list-of-drug-interactions/anti-arrhythmics/amiodarone\" title=\"Amiodarone\" count=\"1\" rel=\"backlink\">Amiodarone</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#bnf_d1e90588\" href=\"#bnf_d1e90588\" namespace=\"/interactions/list-of-drug-interactions/calcium-channel-blockers/verapamil\" title=\"\" count=\"1\" rel=\"backlink\">bnf_d1e90588</xref>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_467\" namespace=\"/interactions/list-of-drug-interactions/calcium-channel-blockers/verapamil\" title=\"Verapamil\" count=\"1\" rel=\"backlink\">Verapamil</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78291\" namespace=\"/treatment-summaries/arrhythmias\" title=\"Arrhythmias\" count=\"1\" rel=\"backlink\">Arrhythmias</xref>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP78403\" namespace=\"/treatment-summaries/venous-thromboembolism\" title=\"Venous thromboembolism\" count=\"1\" rel=\"backlink\">Venous thromboembolism</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1120\" namespace=\"/interactions/list-of-drug-interactions/anticoagulants/dabigatran\" title=\"Dabigatran\" count=\"1\" rel=\"link\">Dabigatran</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP77319\" namespace=\"/drugs/dabigatran-etexilate/capsule\" title=\"Capsule\" count=\"1\" rel=\"link\">Capsule</xref>\n</links>\n</topic>",
    "id": "PHP1505",
    "outputclass": "drug",
    "rev": "1.11",
    "type": "drug",
    "namespace": "/drugs/dabigatran-etexilate",
    "basename": "dabigatran-etexilate",
    "title": "DABIGATRAN ETEXILATE",
    "interactants": [
        {
            "id": "bnf_int_1120",
            "label": "Dabigatran"
        }
    ],
    "vtmid": "13568411000001103",
    "drugClassification": [
        "Thrombin inhibitors"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "drugAction": {
        "drugAction": [
            {
                "type": "drugAction",
                "textContent": "Dabigatran etexilate is a direct thrombin inhibitor with a rapid onset of action.",
                "html": "<p>Dabigatran etexilate is a direct thrombin inhibitor with a rapid onset of action.</p>"
            }
        ]
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism following total knee replacement surgery",
                        "html": "Prophylaxis of venous thromboembolism following total knee replacement surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "110 mg, to be taken 1&#8211;4 hours after surgery, followed by 220 mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.",
                        "html": "<p>110&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 220&#8239;mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.</p>",
                        "ageGroup": "18&#8211;74 years"
                    },
                    {
                        "textContent": "75 mg, to be taken 1&#8211;4 hours after surgery, followed by 150 mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.",
                        "html": "<p>75&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 150&#8239;mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.</p>",
                        "ageGroup": "75 years and over"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism following total knee replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil",
                        "html": "Prophylaxis of venous thromboembolism following total knee replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "110 mg, to be taken 1&#8211;4 hours after surgery, followed by 150 mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.",
                        "html": "<p>110&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 150&#8239;mg once daily for 9 days, to be followed 12&#8211;24 hours after initial dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism following total hip replacement surgery",
                        "html": "Prophylaxis of venous thromboembolism following total hip replacement surgery"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "110 mg, to be taken 1&#8211;4 hours after surgery, followed by 220 mg once daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.",
                        "html": "<p>110&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 220&#8239;mg once daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.</p>",
                        "ageGroup": "18&#8211;74 years"
                    },
                    {
                        "textContent": "75 mg, to be taken 1&#8211;4 hours after surgery, followed by 150 mg once daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.",
                        "html": "<p>75&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 150&#8239;mg once daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.</p>",
                        "ageGroup": "75 years and over"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of venous thromboembolism following total hip replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil",
                        "html": "Prophylaxis of venous thromboembolism following total hip replacement surgery in patients receiving concomitant treatment with amiodarone or verapamil"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "110 mg, to be taken 1&#8211;4 hours after surgery, followed by 150 mg daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.",
                        "html": "<p>110&#8239;mg, to be taken 1&#8211;4 hours after surgery, followed by 150&#8239;mg daily for 27&#8211;34 days, to be followed 12&#8211;24 hours after initial dose.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of deep-vein thrombosis",
                        "html": "Treatment of deep-vein thrombosis"
                    },
                    {
                        "textContent": "Treatment of pulmonary embolism",
                        "html": "Treatment of pulmonary embolism"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent deep-vein thrombosis",
                        "html": "Prophylaxis of recurrent deep-vein thrombosis"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent pulmonary embolism",
                        "html": "Prophylaxis of recurrent pulmonary embolism"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.",
                        "html": "<p>150&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>",
                        "ageGroup": "18&#8211;74 years"
                    },
                    {
                        "textContent": "110&#8211;150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.",
                        "html": "<p>110&#8211;150&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>",
                        "ageGroup": "75&#8211;79 years"
                    },
                    {
                        "textContent": "110 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.",
                        "html": "<p>110&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>",
                        "ageGroup": "80 years and over"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of deep-vein thrombosis in patients with moderate renal impairment",
                        "html": "Treatment of deep-vein thrombosis in patients with moderate renal impairment"
                    },
                    {
                        "textContent": "Treatment of deep-vein thrombosis in patients at increased risk of bleeding",
                        "html": "Treatment of deep-vein thrombosis in patients at increased risk of bleeding"
                    },
                    {
                        "textContent": "Treatment of pulmonary embolism in patients with moderate renal impairment",
                        "html": "Treatment of pulmonary embolism in patients with moderate renal impairment"
                    },
                    {
                        "textContent": "Treatment of pulmonary embolism in patients at increased risk of bleeding",
                        "html": "Treatment of pulmonary embolism in patients at increased risk of bleeding"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent deep-vein thrombosis in patients with moderate renal impairment",
                        "html": "Prophylaxis of recurrent deep-vein thrombosis in patients with moderate renal impairment"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent deep-vein thrombosis in patients at increased risk of bleeding",
                        "html": "Prophylaxis of recurrent deep-vein thrombosis in patients at increased risk of bleeding"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent pulmonary embolism in patients with moderate renal impairment",
                        "html": "Prophylaxis of recurrent pulmonary embolism in patients with moderate renal impairment"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent pulmonary embolism in patients at increased risk of bleeding",
                        "html": "Prophylaxis of recurrent pulmonary embolism in patients at increased risk of bleeding"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "110&#8211;150 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.",
                        "html": "<p>110&#8211;150&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Treatment of deep-vein thrombosis in patients receiving concomitant treatment with verapamil",
                        "html": "Treatment of deep-vein thrombosis in patients receiving concomitant treatment with verapamil"
                    },
                    {
                        "textContent": "Treatment of pulmonary embolism in patients receiving concomitant treatment with verapamil",
                        "html": "Treatment of pulmonary embolism in patients receiving concomitant treatment with verapamil"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent deep-vein thrombosis in patients receiving concomitant treatment with verapamil",
                        "html": "Prophylaxis of recurrent deep-vein thrombosis in patients receiving concomitant treatment with verapamil"
                    },
                    {
                        "textContent": "Prophylaxis of recurrent pulmonary embolism in patients receiving concomitant treatment with verapamil",
                        "html": "Prophylaxis of recurrent pulmonary embolism in patients receiving concomitant treatment with verapamil"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "110 mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.",
                        "html": "<p>110&#8239;mg twice daily, following at least 5 days treatment with a parenteral anticoagulant.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension",
                        "html": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "150 mg twice daily.",
                        "html": "<p>150&#8239;mg twice daily.</p>",
                        "ageGroup": "18&#8211;74 years"
                    },
                    {
                        "textContent": "110&#8211;150 mg twice daily.",
                        "html": "<p>110&#8211;150&#8239;mg twice daily.</p>",
                        "ageGroup": "75&#8211;79 years"
                    },
                    {
                        "textContent": "110 mg twice daily.",
                        "html": "<p>110&#8239;mg twice daily.</p>",
                        "ageGroup": "80 years and over"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension in patients receiving concomitant treatment with verapamil",
                        "html": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension in patients receiving concomitant treatment with verapamil"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "110 mg twice daily.",
                        "html": "<p>110&#8239;mg twice daily.</p>"
                    }
                ]
            },
            {
                "indications": [
                    {
                        "textContent": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension, in patients at increased risk of bleeding",
                        "html": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension, in patients at increased risk of bleeding"
                    },
                    {
                        "textContent": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension, in patients with moderate renal impairment",
                        "html": "Prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation and with one or more risk factors such as previous stroke or transient ischaemic attack, symptomatic heart failure, age &#8805; 75 years, diabetes mellitus, or hypertension, in patients with moderate renal impairment"
                    }
                ],
                "specificity": {
                    "routes": [
                        "mouth"
                    ],
                    "textContent": "By mouth",
                    "html": "By mouth"
                },
                "adult": [
                    {
                        "textContent": "110&#8211;150 mg twice daily.",
                        "html": "<p>110&#8211;150&#8239;mg twice daily.</p>"
                    }
                ]
            }
        ],
        "doseEquivalence": [
            {
                "type": "doseEquivalence",
                "title": "Dose equivalence and conversion",
                "textContent": "For information on changing from, or to, other anticoagulants, consult product literature.",
                "html": "<p>For information on changing from, or to, other anticoagulants, consult product literature.</p>"
            }
        ]
    },
    "contraindications": {
        "contraindications": [
            {
                "type": "contraindications",
                "textContent": "Active bleeding",
                "html": "Active bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "do not use as anticoagulant for prosthetic heart valve",
                "html": "do not use as anticoagulant for prosthetic heart valve"
            },
            {
                "type": "contraindications",
                "textContent": "malignant neoplasms",
                "html": "malignant neoplasms"
            },
            {
                "type": "contraindications",
                "textContent": "oesophageal varices",
                "html": "oesophageal varices"
            },
            {
                "type": "contraindications",
                "textContent": "recent brain surgery",
                "html": "recent brain surgery"
            },
            {
                "type": "contraindications",
                "textContent": "recent gastro-intestinal ulcer",
                "html": "recent gastro-intestinal ulcer"
            },
            {
                "type": "contraindications",
                "textContent": "recent intracranial haemorrhage",
                "html": "recent intracranial haemorrhage"
            },
            {
                "type": "contraindications",
                "textContent": "recent ophthalmic surgery",
                "html": "recent ophthalmic surgery"
            },
            {
                "type": "contraindications",
                "textContent": "recent spine surgery",
                "html": "recent spine surgery"
            },
            {
                "type": "contraindications",
                "textContent": "significant risk of major bleeding",
                "html": "significant risk of major bleeding"
            },
            {
                "type": "contraindications",
                "textContent": "vascular aneurysm",
                "html": "vascular aneurysm"
            }
        ]
    },
    "cautions": {
        "cautions": [
            {
                "type": "cautions",
                "textContent": "Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;give initial dose at least 2 hours after catheter removal and monitor neurological signs)",
                "html": "Anaesthesia with postoperative indwelling epidural catheter (risk of paralysis&#8212;give initial dose at least 2 hours after catheter removal and monitor neurological signs)"
            },
            {
                "type": "cautions",
                "textContent": "bacterial endocarditis",
                "html": "bacterial endocarditis"
            },
            {
                "type": "cautions",
                "textContent": "bleeding disorders",
                "html": "bleeding disorders"
            },
            {
                "type": "cautions",
                "textContent": "body-weight less than 50 kg",
                "html": "body-weight less than 50&#8239;kg"
            },
            {
                "type": "cautions",
                "textContent": "elderly",
                "html": "elderly"
            },
            {
                "type": "cautions",
                "textContent": "gastritis",
                "html": "gastritis"
            },
            {
                "type": "cautions",
                "textContent": "gastro-oesophageal reflux",
                "html": "gastro-oesophageal reflux"
            },
            {
                "type": "cautions",
                "textContent": "oesophagitis",
                "html": "oesophagitis"
            },
            {
                "type": "cautions",
                "textContent": "recent biopsy",
                "html": "recent biopsy"
            },
            {
                "type": "cautions",
                "textContent": "recent major trauma",
                "html": "recent major trauma"
            },
            {
                "type": "cautions",
                "textContent": "thrombocytopenia",
                "html": "thrombocytopenia"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (dabigatran).\n\nCaution in concomitant use of drugs that increase risk of bleeding.",
                "html": "<p>Appendix 1 (dabigatran).</p><p>Caution in concomitant use of drugs that increase risk of bleeding.</p>"
            }
        ]
    },
    "sideEffects": {
        "general": {
            "frequencies": {
                "commonOrVeryCommon": [
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "Abdominal pain",
                        "html": "Abdominal pain",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "anaemia",
                        "html": "anaemia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "diarrhoea",
                        "html": "diarrhoea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "dyspepsia",
                        "html": "dyspepsia",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "haemorrhage",
                        "html": "haemorrhage",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    },
                    {
                        "type": "commonOrVeryCommon",
                        "textContent": "nausea",
                        "html": "nausea",
                        "frequency": "commonOrVeryCommon",
                        "specificity": {
                            "textContent": "Common or very common",
                            "html": "Common or very common"
                        }
                    }
                ],
                "uncommon": [
                    {
                        "type": "uncommon",
                        "textContent": "Dysphagia",
                        "html": "Dysphagia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastro-intestinal ulcer",
                        "html": "gastro-intestinal ulcer",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "gastro-oesophageal reflux",
                        "html": "gastro-oesophageal reflux",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "hepatobiliary disorders",
                        "html": "hepatobiliary disorders",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "oesophagitis",
                        "html": "oesophagitis",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "thrombocytopenia",
                        "html": "thrombocytopenia",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    },
                    {
                        "type": "uncommon",
                        "textContent": "vomiting",
                        "html": "vomiting",
                        "frequency": "uncommon",
                        "specificity": {
                            "textContent": "Uncommon",
                            "html": "Uncommon"
                        }
                    }
                ]
            }
        }
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid unless essential&#8212;toxicity in animal studies.",
                "html": "<p>Manufacturer advises avoid unless essential&#8212;toxicity in <i>animal </i>studies.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Manufacturer advises avoid&#8212;no information available.",
                "html": "<p>Manufacturer advises avoid&#8212;no information available.</p>"
            }
        ]
    },
    "hepaticImpairment": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid in severe liver disease, especially if prothrombin time already prolonged.",
                "html": "<p>Avoid in severe liver disease, especially if prothrombin time already prolonged.</p>"
            }
        ]
    },
    "renalImpairment": {
        "doseAdjustments": [
            {
                "type": "doseAdjustments",
                "textContent": "For prophylaxis of venous thromboembolism following knee or hip replacement surgery, reduce initial dose to 75 mg and subsequent doses to 150 mg once daily if creatinine clearance 30&#8211;50 mL/ minute; reduce dose to 75 mg once daily if creatinine clearance 30&#8211;50 mL/minute and patient receiving concomitant treatment with verapamil.\n\nFor treatment of deep-vein thrombosis and pulmonary embolism, prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism, prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation, consider reduced dose of 110 mg twice daily if creatinine clearance 30&#8211;50 mL/minute, based on individual assessment of thromboembolic risk and risk of bleeding.",
                "html": "<p>For <i>prophylaxis of venous thromboembolism following knee or hip replacement surgery</i>, reduce initial dose to 75&#8239;mg and subsequent doses to 150&#8239;mg once daily if creatinine clearance 30&#8211;50&#8239;mL/ minute; reduce dose to 75&#8239;mg once daily if creatinine clearance 30&#8211;50&#8239;mL/minute and patient receiving concomitant treatment with verapamil.</p><p>For <i>treatment of deep-vein thrombosis and pulmonary embolism, prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism, prophylaxis of stroke and systemic embolism in non-valvular atrial fibrillation,</i> consider reduced dose of 110&#8239;mg twice daily if creatinine clearance 30&#8211;50&#8239;mL/minute, based on individual assessment of thromboembolic risk and risk of bleeding.</p>"
            }
        ],
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid if creatinine clearance less than 30 mL/minute.",
                "html": "<p>Avoid if creatinine clearance less than 30&#8239;mL/minute.</p>"
            }
        ],
        "additionalMonitoring": [
            {
                "type": "additionalMonitoring",
                "textContent": "In renal impairment monitor renal function at least annually (manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance).",
                "html": "<p>In renal impairment monitor renal function at least annually (manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance).</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.\n\nNo routine anticoagulant monitoring required (INR tests are unreliable).\n\nAssess renal function (manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance) before treatment in all patients and at least annually in elderly.",
                "html": "<p>Patients should be monitored for signs of bleeding or anaemia; treatment should be stopped if severe bleeding occurs.</p><p>No routine anticoagulant monitoring required (INR tests are unreliable).</p><p>Assess renal function (manufacturer recommends Cockroft and Gault formula to calculate creatinine clearance) before treatment in all patients and at least annually in elderly.</p>"
            }
        ]
    },
    "directionsForAdministration": {
        "directionsForAdministration": [
            {
                "type": "directionsForAdministration",
                "textContent": "When given concomitantly with amiodarone or verapamil, doses should be taken at the same time.",
                "html": "<p>When given concomitantly with amiodarone or verapamil, doses should be taken at the same time.</p>"
            }
        ]
    },
    "prescribingAndDispensingInformation": {
        "prescribingAndDispensingInformation": [
            {
                "type": "prescribingAndDispensingInformation",
                "textContent": "Dabigatran etexilate, is given orally for prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery; it is also licensed for the treatment of deep-vein thrombosis and pulmonary embolism, and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism in adults. Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilisation, and longer duration of treatment should be based on permanent risk factors, or idiopathic deep-vein thrombosis or pulmonary embolism.",
                "html": "<p>Dabigatran etexilate, is given orally for prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery; it is also licensed for the treatment of deep-vein thrombosis and pulmonary embolism, and prophylaxis of recurrent deep-vein thrombosis and pulmonary embolism in adults. Duration of treatment should be determined by balancing the benefit of treatment with the bleeding risk; shorter duration of treatment (at least 3 months) should be based on transient risk factors i.e recent surgery, trauma, immobilisation, and longer duration of treatment should be based on permanent risk factors, or idiopathic deep-vein thrombosis or pulmonary embolism.</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA157",
                        "label": "www.nice.org.uk/TA157"
                    }
                ],
                "fundingIdentifier": "NICE TA157",
                "textContent": "Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (September 2008) Dabigatran etexilate is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.\n\nwww.nice.org.uk/TA157",
                "html": "<p outputclass=\"title\">Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults (September 2008)</p> <p>Dabigatran etexilate is an option for the prophylaxis of venous thromboembolism in adults after total hip replacement or total knee replacement surgery.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA157\">www.nice.org.uk/TA157</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA249",
                        "label": "www.nice.org.uk/TA249"
                    }
                ],
                "fundingIdentifier": "NICE TA249",
                "textContent": "Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (March 2012) Dabigatran etexilate is an option for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with one or more of the following risk factors: previous stroke, transient ischaemic attack, or systemic embolism left ventricular ejection fraction <40% symptomatic heart failure age &#8805;75 years age &#8805;65 years in patients with diabetes mellitus, coronary artery disease, or hypertension The risks and benefits of dabigatran compared to warfarin should be discussed with the patient.\n\nwww.nice.org.uk/TA249",
                "html": "<p outputclass=\"title\">Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation (March 2012)</p> <p>Dabigatran etexilate is an option for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and with one or more of the following risk factors:</p> <ul> <li>previous stroke, transient ischaemic attack, or systemic embolism</li> <li>left ventricular ejection fraction &lt;40%</li> <li>symptomatic heart failure</li> <li>age &#8805;75 years</li> <li>age &#8805;65 years in patients with diabetes mellitus, coronary artery disease, or hypertension</li> </ul> <p>The risks and benefits of dabigatran compared to warfarin should be discussed with the patient.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA249\">www.nice.org.uk/TA249</xref>"
            },
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA327",
                        "label": "www.nice.org.uk/TA327"
                    }
                ],
                "fundingIdentifier": "NICE TA327",
                "textContent": "Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and /or pulmonary embolism (December 2014) Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.\n\nwww.nice.org.uk/TA327",
                "html": "<p outputclass=\"title\">Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and /or pulmonary embolism (December 2014)</p> <p>Dabigatran etexilate is recommended, within its marketing authorisation, as an option for treating and for preventing recurrent deep vein thrombosis and pulmonary embolism in adults.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA327\">www.nice.org.uk/TA327</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP77319",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP98619",
                "label": "Prescribing in dental practice",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78291",
                "label": "Arrhythmias",
                "type": "treatmentSummary"
            },
            {
                "id": "PHP78403",
                "label": "Venous thromboembolism",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ],
        "#bnf_d1e27097": [
            {
                "id": "bnf_d1e27097",
                "label": "bnf_d1e27097",
                "type": "#bnf_d1e27097"
            }
        ],
        "#bnf_d1e27418": [
            {
                "id": "bnf_d1e27418",
                "label": "bnf_d1e27418",
                "type": "#bnf_d1e27418"
            }
        ],
        "#bnf_d1e11888": [
            {
                "id": "bnf_d1e11888",
                "label": "bnf_d1e11888",
                "type": "#bnf_d1e11888"
            }
        ],
        "interaction": [
            {
                "id": "bnf_int_118",
                "label": "Amiodarone",
                "type": "interaction"
            },
            {
                "id": "bnf_int_467",
                "label": "Verapamil",
                "type": "interaction"
            }
        ],
        "#bnf_d1e90588": [
            {
                "id": "bnf_d1e90588",
                "label": "bnf_d1e90588",
                "type": "#bnf_d1e90588"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1120",
                "label": "Dabigatran",
                "type": "interaction"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP77319",
                "label": "Capsule",
                "type": "medicinalForm"
            }
        ]
    }
}